Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach
Asciminib para el tratamiento de la leucemia mieloide crónica en tercera línea: análisis coste-efectividad basado en el enfoque de remisión libre de tratamiento
Antonio Garcia Molina
Corresponding author
antonio.gm.94@gmail.com

Corresponding author at: Pharmacy Unit, Hospital Joan XXIII., Carrer Dr. Mallafré Guasch, 4, 43005 Tarragona, Spain.
Pharmacy Unit, Hospital Joan XXIII, Tarragona, Spain
Read
1938
Times
was read the article
562
Total PDF
1376
Total HTML
Share statistics
Article information
ISSN: 11306343
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 May 24 3 27
2025 April 147 48 195
2025 March 131 40 171
2025 February 112 35 147
2025 January 76 40 116
2024 December 124 45 169
2024 November 71 46 117
2024 October 78 41 119
2024 September 138 54 192
2024 August 109 40 149
2024 July 110 35 145
2024 June 138 61 199
2024 May 98 56 154
2024 April 20 18 38
Show all

Follow this link to access the full text of the article

Idiomas
Farmacia Hospitalaria
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.